To fill this need we introduce Episodes of Care ( EpiCare), a benchmark designed to mimic the challenges associated with applying RL to longitudinal healthcare settings.

We printed a checkerboard with a 9x10 grid of blocks, each measuring 87 mm x 87 mm. Parameter V alue Model Architecture Panoptic-PolarNet Test Batch Size 2 V al Batch Size 2 Test Batch size 1 post proc threshold 0.1 post proc nms kernel 5 post proc top k 100 center loss MSE offset loss L1 center loss weight 100 offset loss weight 10 enable SAP True SAP start epoch 30 SAP rate 0.01 Table 3: Parameters for Panoptic Segmentation model Parameter V alue(s) Model Architecture 4D-StOP Learning Rate 0.0005 Momentum 0.98 Stride 1 Max in points 5000 Sampling importance Decay Sampling None Input Threads 16 Checkpoint Gap 100 Table 4: Parameters for the 4D Panoptic Segmentation model The results reveal a significant variance in performance across different categories. Notably, 'Structure' and'Ground' both achieved high mIoU at Result The results are shown in Table 8. presents the mean intersection-over-union (mIoU) percent-56 Notably, 'Structure' achieved the highest mIoU at'General Objects' category have the lowest mIoU, The dataset is divided into 17 and 6 categories, respectively. Ground' and'Roads', as opposed to grouping anything related to ground as a single category. Overall, the performance across these tasks underscores the challenges posed by our dataset's With our dataset, future work can focus on improving the model's capacity to handle such diverse The raw data, processed data, and framework code can be found on our website.

We printed a checkerboard with a 9x10 grid of blocks, each measuring 87 mm x 87 mm. Parameter V alue Model Architecture Panoptic-PolarNet Test Batch Size 2 V al Batch Size 2 Test Batch size 1 post proc threshold 0.1 post proc nms kernel 5 post proc top k 100 center loss MSE offset loss L1 center loss weight 100 offset loss weight 10 enable SAP True SAP start epoch 30 SAP rate 0.01 Table 3: Parameters for Panoptic Segmentation model Parameter V alue(s) Model Architecture 4D-StOP Learning Rate 0.0005 Momentum 0.98 Stride 1 Max in points 5000 Sampling importance Decay Sampling None Input Threads 16 Checkpoint Gap 100 Table 4: Parameters for the 4D Panoptic Segmentation model The results reveal a significant variance in performance across different categories. Notably, 'Structure' and'Ground' both achieved high mIoU at Result The results are shown in Table 8. presents the mean intersection-over-union (mIoU) percent-56 Notably, 'Structure' achieved the highest mIoU at'General Objects' category have the lowest mIoU, The dataset is divided into 17 and 6 categories, respectively. Ground' and'Roads', as opposed to grouping anything related to ground as a single category. Overall, the performance across these tasks underscores the challenges posed by our dataset's With our dataset, future work can focus on improving the model's capacity to handle such diverse The raw data, processed data, and framework code can be found on our website.

Almost 50% depression patients face the risk of going into relapse. The risk increases to 80% after the second episode of depression. Although, depression detection from social media has attained considerable attention, depression relapse detection has remained largely unexplored due to the lack of curated datasets and the difficulty of distinguishing relapse and non-relapse users. In this work, we present ReDepress, the first clinically validated social media dataset focused on relapse, comprising 204 Reddit users annotated by mental health professionals. Unlike prior approaches, our framework draws on cognitive theories of depression, incorporating constructs such as attention bias, interpretation bias, memory bias and rumination into both annotation and modeling. Through statistical analyses and machine learning experiments, we demonstrate that cognitive markers significantly differentiate relapse and non-relapse groups, and that models enriched with these features achieve competitive performance, with transformer-based temporal models attaining an F1 of 0.86. Our findings validate psychological theories in real-world textual data and underscore the potential of cognitive-informed computational methods for early relapse detection, paving the way for scalable, low-cost interventions in mental healthcare.

Body Dysmorphic Disorder (BDD) is a highly prevalent and frequently underdiagnosed condition characterized by persistent, intrusive preoccupations with perceived defects in physical appearance. In this extended analysis, we employ multiple machine learning approaches to predict treatment outcomes -- specifically treatment response and remission -- with an emphasis on interpretability to ensure clinical relevance and utility. Across the various models investigated, treatment credibility emerged as the most potent predictor, surpassing traditional markers such as baseline symptom severity or comorbid conditions. Notably, while simpler models (e.g., logistic regression and support vector machines) achieved competitive predictive performance, decision tree analyses provided unique insights by revealing clinically interpretable threshold values in credibility scores. These thresholds can serve as practical guideposts for clinicians when tailoring interventions or allocating treatment resources. We further contextualize our findings within the broader literature on BDD, addressing technology-based therapeutics, digital interventions, and the psychosocial determinants of treatment engagement. An extensive array of references situates our results within current research on BDD prevalence, suicidality risks, and digital innovation. Our work underscores the potential of integrating rigorous statistical methodologies with transparent machine learning models. By systematically identifying modifiable predictors -- such as treatment credibility -- we propose a pathway toward more targeted, personalized, and ultimately efficacious interventions for individuals with BDD.

Iacucci and her colleagues recruited patients from 11 international centers between September 2016 and November 2019. Eligible participants had a confirmed diagnosis of ulcerative colitis for at least one year without regard to disease activity and an indication for a colonoscopy. At least two tissue samples were obtained from the rectum and the sigmoid because they are common areas representative of healing and inflammation. The endoscopic exam was recorded in the same area. Clinical outcomes used as proxies for disease flare-ups for the purpose of prognosis assessment included ulcerative colitis-related hospitalizations or surgery and increase in initiation of or changes in ulcerative colitis treatments, such as immunomodulators, biologics, or steroids, due to worsening symptoms.

The most successful targets for precision medicine can be found by using algorithms created by University of Michigan researchers. These algorithms successfully identify the weakest targets in ovarian cancer cells--genes these cells depend on to live in the human body. Cancer cells delete DNA when they go to the dark side, so a team of doctors and engineers targeted the'backup plans' that run essential cell functions. Researchers at the University of Michigan and Indiana University have discovered a cancer weakness. They found that the way that tumor cells enable their uncontrolled growth is also a weakness that can be harnessed to treat cancer.

Keeping blood sugar under control can improve outcomes in patients, but that's not always easy to do. Now, doctors are using artificial intelligence to help! Researchers are now using the technology to help people with Type 2 diabetes get their disease under control. "Diabetes is the leading cause of blindness," explained Mary Vouyiouklis Kellis, an endocrinologist at the Cleveland Clinic. "It can also affect kidney function. It can affect nerves, it can increase the risk for lower limb amputation."

An artificial intelligence tool has the potential to put Type 2 diabetes into remission, according to research presented at an American Diabetes Association meeting June 3 in New Orleans. The randomized controlled trial was designed to compare the Whole Body Digital Twin, a technology that collects metabolism data from noninvasive wearable sensors, versus standard care in sustaining Type 2 diabetes remission. Remission is defined as at least three months with normal blood glucose levels without taking diabetes medication. The interim analysis of 262 patients found the technology increased diabetes remission by about 84 percent. The tool uses a predictive model to provide individualized guidance on nutrition, sleep, physical activity and breathing to patients and their providers.